Global Therapeutic Antibody Bundle Report 2016 - Focus on ADCs, Bispecifics, Biosimilars & Biosuperiors Featuring 271 Therapeutics Companies - Research and Markets
DUBLIN, June 14, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors" report to their offering.
The Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors, includes the following 4 publications at a 50% discount when purchased altogether as part of a bundle:
- Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
- T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals
- Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
- Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
Below are summaries of each report as well as links to purchase the individual titles:
"Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis"
This report describes and analyzes the situation of antibody-drug conjugates as of November 2015 regarding
- ADC pipeline
- ADC technologies
- ADC stakeholders
- ADC business opportunities and commercial perspectives
Although the initial enthusiasm about antibody-drug conjugates has made room for a more realistic understanding, the prospects for success of ADC drug candidates remain good and are based on a well-filled pipeline, increasing adoption of next generation ADC technologies, lessons learned from failures, a balanced mixture of stakeholders and a variety of options for funding of ADC developments. About 70 ADCs are in clinical and pre-IND stages of development and at least the same number of ADC programs are in preclinical R&D.
For the first time in 2015, combined sales of the approved and marketed ADC products Adcetris and Kadcyla will surpass the sales limit of US$ 1 billion. The pipeline of ADCs and immunoconjugates in advanced clinical development gives the chance of approval of further ADCs in the near- and mid-term future. The clinical attrition rate of ADCs is lower, i.e. better, than that of conventional, naked antibodies in oncology. The availability of next generation ADC technologies allows to select case by case the appropriate linker and payload. Site-specific conjugation technologies with and without engineering of the antibody generate homogenous products. Novel payloads provide the basis for enhanced antitumor activity.
Prodrug concepts and polymeric carrier systems may not only contribute to a higher therapeutic index, but also boost efficacy by targeted delivery of a higher number of payloads than in conventional ADCs. Competition by ADCs directed against the same target is relatively low, except for clinically and commercially validated Her2 which is ideal to validate new technologies. However, targets are still a bottleneck with the attractive consequence that companies with successful target identification capabilities are highly rewarded by investors and business partners.
Nearly all major pharma and biotech companies have ADC programs, although with different strategies of how to gain access to ADC technologies. Few have established proprietary in-house capabilities, most still rely on outside technology providers. However, the duopoly of conventional ADC technology providers is converting into a more differentiated, heterogenous field of ADC technologies and technology providers.
This report entitled Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis is based on the analysis of more than 90 companies, more than 100 ADC drug profiles and more than 26 ADC technologies and components. Sources of information are provided by 274 scientific references and numerous non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets (with hyperlinks leading to source of information). The report also describes and analyzes business deals in the ADC field, e.g. collaboration and license agreements, mergers and acquisitions, financial transactions (divestments, public offerings, private equity and venture capital fund-raising).
Coverage of this ADC report:
- Next-to-market ADCs
- ADC Drug Profiles: clinical, pre-IND, preclinical
- Target Competition by ADCs
- ADC Development Failures
- Conventional & Emerging ADC Technologies
- Polymeric ADC Carriers
- Novel ADC Payloads & Linkers
- Site-specific ADC Conjugation Technologies
- Major Pharma & Biotech Companies with ADC Programs
- Small and Medium Biopharmaceutical Companies with ADC Programs
- Integrated ADC Technology & Pipeline Companies
- Companies with Linker, Payload, Carrier and Conjugation Technologies
- Commercial Opportunities and Perspectives with ADCs
- Commericalization of Approved ADCs
- Fund-Raising for ADC Companies
- Pharma-Biotech & Biotech-Biotech Collaboration & Licensing Agreements
"T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals"
Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR).
Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.
Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months.
This report "T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals" as of May 2016 brings you up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.
The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.
Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.
The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.
All information in the report is fully referenced with 159 scientific references, in many cases with hyperlinks leading to the source of information (abstracts, Posters, papers). Non-scientific references, such as press releases, annual reports or company presentations are disclosed within the text with an embedded hyperlink leading to the online source of information.
What will you find in the report?
- Profiles of 34 companies active in the field;
- Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
- Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development;
- Technology selection and preferences of major pharma;
- Key characteristics of technologies with clinical stage drug candidates
- Emerging alternative bi- and trispecific formats
- Target selection and competition in drug candidates
- Competition of recombinant bispecific molecules with alternative treatment modalities
- Dosing schedules of clinical stage drug candidates based on molecular features
- Economic terms of collaboration and licensing deals;
Who will benefit from the report?
- Venture capital, private equity and investment managers;
- Financial analysts;
- CFO;
- Business development and licensing (BDL) specialists;
- Marketing managers;
- CEO, COO and managing directors;
- Corporate strategy, product and portfolio analysts and managers;
- Chief Technology Officer;
- Cell technology and manufacturing specialists;
- Clinical and preclinical development specialists.
"Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update"
This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target.
The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 - 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.
The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R).
Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.
The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
"Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases"
This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory & Other Diseases evaluates the competitive landscape of bispecific therapeutic antibodies for treatment of cancer, anti-inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic, ophthalmic and pulmonary diseases as of June 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Tremendous progress in bispecific antibody technologies during the last decade have lead to an explosion of bispecific antibodies in clinical development. This report describes 47 clinical and further 25 pre-IND stage bispecific antibodies in addition to numerous preclinical R&D endeavours. The two specificities provide flexibility in the use as:
- T-Cell or NK cell redirecting bispecific cancer antibodies
- Bispecific immuno-oncology antibodies
- Bispecific tumor antigens targeted cancer antibodies
- Bispecific antibodies for inflammatory & autoimmune diseases
- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases
The report includes a compilation of currently active projects in development of bispecific therapeutic antibodies including cocktails of antibodies as well as oligo- and polyclonal antibodies. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Company
- Product Category
- Indication
- R&D Stage
Companies Mentioned
- 3SBio
- 3SBio (Shenyang Sunshine Pharmaceutical Co)
- ACES Pharma
- ADC Therapeutics
- AET Biotech
- APO-T
- AREVA Med
- AVEO Pharmaceuticals
- AbClon
- AbbVie
- Ablynx
- Adimab
- Affibody
- Affilogic
- Affimed Therapeutics
- Affitech
- Alethia Biotherapeutics
- Allergan
- Alligator Biosciences
- Alopexx Oncology
- Alteogen
- Alvogen
- Ambrx
- Amega Biotech
- Amgen
- AngioChem
- Angiochem
- Antikor Biopharma
- Apexigen
- Aprogen
- Archemix
- Aryogen
- Asana Biosciences
- Ascendis Pharma
- Astellas Pharma
- AstraZeneca
- AstraZeneca (MedImmune)
- Avaxia Biologics
- Axxo
- BIND Therapeutics
- Baliopharm
- Baxalta
- Bayer
- Bayer HealthCare Pharmaceuticals
- Bicycle Therapeutics
- Binex
- Bio Farma
- BioCND
- BioXpress Therapeutics
- Biocad
- Biocon
- Bioeq
- Biogen
- Bionovis
- Biotest
- Blend Therapeutics
- Boehringer Ingelheim
- Bristol-Myers Sqibb
- Bristol-Myers Squibb
- CIMAB
- Catalent Pharma Solutions (Redwood Bioscience)
- Celgene
- Celldex Pharmaceuticals
- Celltrion
- Centrose
- Ceres Oncology
- Chengdu Kanghong Biotech Co.
- Cipla
- Clearside Biomedical
- Coherus Biosciences
- Complix
- Cristalia
- Curaxys
- CureMeta
- CytRx
- CytomX
- CytomX Therapeutics
- Daewoong Pharmaceutical Co
- Daiichi Sankyo
- Delenex Therapeutics
- Dermira
- Dong-A ST
- Dophen Biomed
- Dr Reddy’s Laboratories
- Eddingpharma
- Eisai
- Eli Lilly
- Emergent BioSolutions
- EnGenlC
- Endocyte
- EngMab
- Epirus Biopharmaceuticals
- Esperance Pharmaceuticals
- Eureka Therapeutics
- Exicure
- Ferring Pharmaceuticals
- ForSight VISION4
- Formation Biologics
- Fosun Pharma
- Fujifilm Kyowa Kirin Biologics
- GEMoaB
- Gansu Duyiwei Biological Pharmaceutical Co
- Gedeon Richter
- GenIlac
- Gene Techno Science (GTS)
- Generon
- Genmab
- Genor Biopharma
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Gliknik
- Glycotope
- Green Cross
- Halozyme
- HanAll Pharmaceuticals
- Hanwha Chemical
- Hanwha Chemical Biologics Business
- Harvest Moon Pharmaceuticals
- Heidelberg Pharma
- Helix BioPharma
- Helvetic BioPharma
- Hetero Group
- Hyprocell
- IBC Generium
- Igenica Biotherapeutics
- Ildong Pharmaceutical
- Immune Pharmaceuticals
- ImmuneXcite
- ImmunoGen
- Immunocore
- Immunomedics
- Innate Pharma
- Innogene Kalbiotech
- Innokeys
- Innovent Biologics
- Intas Pharmaceuticals
- JHL Biotech
- Janssen (Johnson & Johnson)
- Janssen (Johnson & Johnson)
- Janssen Biotech
- Jiangsu Simcere Pharmaceutical
- Jiangsu T-mab Biopharma
- Kairos Therapeutics
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
- LG Life Sciences
- LegoChem
- LegoChem Biosciences
- Libbs Farmaceutica
- LinXis
- MabTech
- MabXience
- Mabion
- MacroGenics
- Meditope Biosciences
- Meiji Seika
- Menarini
- Merck (MSD)
- Merck Biopharma & HealthCare Biosimilars
- Merck Serono
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Merus
- Mistubishi Tanabe Pharma
- Mitsubishi Tanabe Pharma
- Mochida
- Molecular Partners
- Molecular Templates
- Momenta Pharmaceuticals
- Morphosys
- MultiCell Immunotherapeutics
- Mundipharm
- Mycenax Biotech
- Mylan Pharmaceuticals
- NBE Therapeutics
- NanoCarrier
- Nanogen Biopharmaceutical Co
- Natco Pharma
- Neovii Biotech
- Nerviano Medical Sciences
- Neurotech
- Nichi-iko Pharmaceutical
- Nippon Kayaku
- Novartis
- Novartis (& Sandoz/Alcon)
- OMT Therapeutics
- OncoMed Pharmaceuticals
- Oncobiologics
- OntoChem
- Ophthea
- Ophthotech
- Orygen Biotecnologia
- Oxford BioTherapeutics
- Oxis Biotech
- PanOptica
- Paras Biopharmaceuticals
- Pfenex
- Pfizer
- Pfizer (& Hospira)
- PharmAbcine
- Pharmamar
- Pharmapraxis
- Philogen
- Pieris Pharmaceuticals
- PlantForm
- Polpharma Group
- Polytherics (Abzena)
- Probiomed
- Progenics Pharmaceuticals
- Protalix Biotherapeutics
- Quanta Biodesign
- Ranbaxy
- Regeneron Pharmaceuticals
- Reliance Life Sciences
- Roche
- STC Biologics
- Samsung Bioepis (JV of Samsung and Biogen)
- Sanofi
- Scil Proteins
- Seattle Genetics
- Senju Pharmaceutical
- Serina Therapeutics
- Servier
- Shanghai Biomabs Pharmaceutical
- Shanghai Celgen BioPharmaceutical Co
- Shanghai Citi Pacific (CO) Guojian Pharmaceutical Co (CPGP)
- Shanghai Fudan-Zhangjiang BioPharmaceuticals
- Shanghai Henlius Biotech
- Shanghai Zhangjiang Biotechnology (ZJ-Bio)
- Sirnaomics
- Sorrento Biologics/Therapeutics
- Sorrento Therapeutics (Concortis Biosystems)
- Spectrum Pharmaceuticals
- Stada Arzneimittel
- Stemcentrx
- Sutro Biopharma
- Syd labs
- Symphogen
- SynAffix
- Synta Pharmaceuticals
- Synthon Biopharmaceuticals
- TG Therapeutics
- TPG Biologics
- TSH Pharma
- Taisho Pharmaceutical
- Takeda Pharmaceutical Co
- Therapeutics Protein International (TPI)
- Tillots Pharma
- Torrent Pharma
- Trimer Biotech
- Triphase Accelerator
- Tyrogenex
- UCB
- Unum Therapeutics
- Vaccinex
- Valeant Pharmaceuticals
- Valor Biotherapeutics
- WuXi PharmaTech
- Wuhan YZY Biopharma
- Xbrane Biopharma
- Xencor
- YL Biologics
- Yuhan
- Zhejiang Huahai Pharmaceutical Co
- Zhejiang Medicine
- Zhejiang Medicine Co.
- Zova Biotherapeutics
- Zydus Cadila
- Zymeworks
- Zyngenia
- biOasis Technologies
For more information visit http://www.researchandmarkets.com/research/5flsds/therapeutic
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article